GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fagron SA (LTS:0HNZ) » Definitions » Net Income From Continuing Operations

Fagron (LTS:0HNZ) Net Income From Continuing Operations : €84.4 Mil (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Fagron Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Fagron's net income from continuing operations for the six months ended in Dec. 2023 was €42.3 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was €84.4 Mil.

Fagron Net Income From Continuing Operations Historical Data

The historical data trend for Fagron's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fagron Net Income From Continuing Operations Chart

Fagron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.74 73.72 76.82 87.77 84.45

Fagron Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.20 44.62 43.15 42.18 42.26

Fagron Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €84.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fagron (LTS:0HNZ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fagron SA (LTS:0HNZ) » Definitions » Net Income From Continuing Operations
Comparable Companies
XBRU:MITRA ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692 NSE:DIVISLAB BOM:500124 VTRS NBIX SZSE:000963 SHSE:600085 XPAR:IPN SHSE:600196 XTAE:TEVA
Traded in Other Exchanges
ARSUF:USA FAGRb:UK 4A5:Germany FAGR:Belgium
Address
Fascinatio Boulevard 350, Rotterdam, ZH, NLD, 3065 WB
Website
https://www.fagron.com
Fagron SA is a pharmaceutical compounding company operating in Belgium. It acts as a supplier of pharmaceutical care to hospitals, pharmacies, clinics, and patients across the world. The company also produces pharmaceutical raw materials, equipment, and supplies which are needed to prepare medication in the pharmacy. Its segments are namely Fagron Europe, Middle East and Africa (EMEA), Fagron North America and Fagron Latin America. Majority of its revenue comes from Fagron EMEA.

Fagron (LTS:0HNZ) Headlines

No Headlines